title: Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis.
abstract: Essential thrombocythaemia (ET) is a disease associated with an elevated risk of thrombosis. This study evaluated the efficacy and safety of pipobroman (PB) in the long-term control of ET patients who had, at diagnosis, one or more of the following currently known risk factors for thrombosis or haemorrhage (high-risk patients): age > 60 years, history of thrombosis or haemorrhage, platelets >1000 x 10(9)/l. From 1978 to 2000, with a median follow-up of 10 years, 118 previously untreated high-risk ET patients (median age 62 years, range 25-82), were treated with PB at the starting dose of 0.8-1 mg/kg/d. All patients reached a platelet count <600 x 10(9)/l and 91% achieved a platelet count <400 x 10(9)/l. During follow-up, 13 patients had thrombosis, with a 10-year cumulative risk of 14%. Acute myeloid leukaemia, myelofibrosis and solid tumours occurred in three, two and seven patients with a 10-year cumulative risk of 3%, 2% and 7% respectively. Actuarial survival at 20 years was 64% and the standardized mortality ratio was 1.1 (95% CI: 0.7-1.7), not statistically different from the general population (P = 0.54). Age was associated with a higher risk of death (P = 0.00009) and thrombosis (P = 0.003). The duration of PB treatment did not correlate with the occurrence of second malignancies. This study, with a median follow-up of 10 years, demonstrates that pipobroman is effective and well tolerated. The low cumulative 10-year risk of thrombosis, leukaemia and solid tumours indicates that pipobroman is an adequate treatment for patients with high risk ET.
authors.affiliation: Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy. f.passamonti@smatteo.pv.it
authors.forename: Francesco
authors.initials: F
authors.lastname: Passamonti
authors.forename: Lucia
authors.initials: L
authors.lastname: Malabarba
authors.forename: Ester
authors.initials: E
authors.lastname: Orlandi
authors.forename: Cristiana
authors.initials: C
authors.lastname: Pascutto
authors.forename: Ercole
authors.initials: E
authors.lastname: Brusamolino
authors.forename: Cesare
authors.initials: C
authors.lastname: Astori
authors.forename: Claudia
authors.initials: C
authors.lastname: Baratè
authors.forename: Angelo
authors.initials: A
authors.lastname: Canevari
authors.forename: Alessandro
authors.initials: A
authors.lastname: Corso
authors.forename: Paolo
authors.initials: P
authors.lastname: Bernasconi
authors.forename: Mario
authors.initials: M
authors.lastname: Cazzola
authors.forename: Mario
authors.initials: M
authors.lastname: Lazzarino
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007951:Leukemia, Myeloid / Q000150:complications; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications; D010885:Pipobroman / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D055728:Primary Myelofibrosis / Q000150:complications; D016016:Proportional Hazards Models; D012306:Risk; D013920:Thrombocythemia, Essential / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control*; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D010885:Pipobroman